Condition (MeSH)
Protein-Losing Enteropathies
ClinicalTrials.gov lists 13 trials for Protein-Losing Enteropathies or a narrower condition beneath it. Regeneron Pharmaceuticals has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
13 of the 13 trials are tagged with Protein-Losing Enteropathies itself; the rest are tagged with a narrower condition beneath it.
When did Protein-Losing Enteropathies trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 3 |
| 2010 | 1 |
| 2009 | 1 |
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Protein-Losing Enteropathies trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 4 | 1 |
| Observational | 7 |
| Expanded access | 1 |
How many Protein-Losing Enteropathies trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 3 |
| Completed | 4 |
| Approved for marketing | 1 |
| Terminated | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Protein-Losing Enteropathies trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Regeneron Pharmaceuticals | 3 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| Jazz Pharmaceuticals | 1 |
Which drugs are being tested for Protein-Losing Enteropathies? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Pozelimab | 3 |
| Camostat | 1 |
| Eculizumab | 1 |
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| ODSH at 0.375 mg/kg/h | 1 |
| Treatment-inhaled tPA | 1 |
| 68Ga-HSA | 1 |
| ODSH at 0.125 mg/kg/h | 1 |
| ODSH at 0.250 mg/kg/h | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Protein-Losing Enteropathies trials report? (7)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Vomiting | 2 | 1 |
| Abdominal pain | 1 | 1 |
| Dehydration | 1 | 1 |
| Head injury | 1 | 1 |
| Upper limb fracture | 1 | 1 |
Showing 5 of 7 adverse events.
Which publications cover Protein-Losing Enteropathies? (20)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The patient experience of CHAPLE disease: results from interviews conducted as part of a clinical trial for an ultra-rare condition. | Orphanet journal of rare diseases | 2025 | Yes |
| Dysbiosis of gut microbiota in patients with protein-losing enteropathy after the Fontan procedure. | International journal of cardiology | 2024 | Yes |
| Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study. | Lancet (London, England) | 2024 | Yes |
| Longitudinal Follow-Up of Children With HLHS and Association Between Norwood Shunt Type and Long-Term Outcomes: The SVR III Study. | Circulation | 2023 | Yes |
| Eculizumab Is Safe and Effective as a Long-term Treatment for Protein-losing Enteropathy Due to CD55 Deficiency. | Journal of pediatric gastroenterology and nutrition | 2019 | Yes |
Showing 5 of 20 publications.
Prevalence (1)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Unspecified |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity and sub-conditions in mesh.